Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<div> <p>In what was widely viewed as a blow to expanding marijuana research for such conditions as post-traumatic stress disorder, the U.S. Drug Enforcement Administration recently rejected a petition to reclassify cannabis from its current status as a Schedule I drug.</p> </div>

Federal Marijuana Decision a Buzzkill for Researchers